相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Letter
Infectious Diseases
Yosuke Hirotsu et al.
JOURNAL OF INFECTION
(2023)
Letter
Infectious Diseases
Markus Hoffmann et al.
LANCET INFECTIOUS DISEASES
(2023)
Letter
Medicine, General & Internal
Ai-ris Y. Collier et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Letter
Medicine, General & Internal
Qian Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Immunology
Ori Wand et al.
Summary: A third dose of the BNT162b2 vaccine induces a strong and prolonged humoral response in healthcare workers, with significantly higher antibody levels for up to six months after vaccination.
Article
Infectious Diseases
Anne J. Huiberts et al.
Summary: Based on data from over 32,000 participants, the relative effectiveness of bivalent original/Omicron BA.1 vaccination against Omicron SARS-CoV-2 infection was 31% in 18-59-year-olds and 14% in 60-85-year-olds. The protection against Omicron infection was higher with bivalent vaccination compared to prior infection. However, the added benefit of bivalent booster vaccination in preventing SARS-CoV-2 infection was limited.
Article
Immunology
Masae Itamochi et al.
Summary: This study assessed the immunogenicity of COVID-19 mRNA vaccines in nursing home residents and staff. The findings showed that the third dose of the vaccine significantly enhanced the immune response against the Omicron BA.1 and BA.5 subvariants, but the effect was reduced in participants aged 80 years and above.
Article
Medicine, Research & Experimental
Yosuke Hirotsu et al.
Summary: The presence of pneumonia and pathogenesis varies depending on the SARS-CoV-2 variant. Infection with different variants results in different prevalence of pneumonia and severity of lung damage, with BA.2 variant showing the lowest prevalence and mild lung pathogenesis.
COMMUNICATIONS MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Immunology
Joana Oliveira-Silva et al.
Summary: This study investigated the immune response after vaccination in 4264 healthcare workers. The results showed that 15 days after vaccination, females and younger participants had higher antibody levels, which gradually decreased over time. These findings highlight the importance of tracking immune kinetics and the potential need for revaccination in certain populations.
Article
Immunology
Ariel Israel et al.
Summary: This study demonstrates that individuals who received the Pfizer-BioNTech mRNA vaccine have higher initial levels of antibodies compared to patients who had been infected with the SARS-CoV-2 virus, but experience a much faster exponential decrease in antibody levels.
Article
Multidisciplinary Sciences
Gene Igawa et al.
Summary: This study found that the seroprevalence of N-specific antibodies remains low among HCWs at a frontline hospital in Tokyo. Almost all HCWs developed S-specific antibodies after receiving the BNT162b2 vaccine. HCWs who had a history of COVID-19 had higher levels of S-specific antibodies. Additionally, a small percentage of HCWs without a history of COVID-19 tested positive for N-specific antibodies, indicating asymptomatic infections.
SCIENTIFIC REPORTS
(2022)
Article
Public, Environmental & Occupational Health
Ruth Link-Gelles et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Medicine, General & Internal
Ann R. Falsey et al.
Summary: The clinical trial in the United States, Chile, and Peru showed that the AZD1222 vaccine was both safe and effective in preventing symptomatic and severe Covid-19 cases, with an overall estimated efficacy of 74% and a higher efficacy of 83.5% in participants 65 years of age or older. The high vaccine efficacy was consistent across various demographic subgroups, and antibodies increased significantly after each dose.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Amarendra Pegu et al.
Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.
Article
Immunology
Yosuke Hirotsu et al.
Summary: A study on healthcare workers vaccinated with the BNT162b2 mRNA vaccine found that antibody responses were significantly enhanced after the second dose in infection-naive individuals and after the first dose in previously infected individuals. The robust boosting effect of immunization suggests that increased antibody titres following exposure to the virus may limit viral replication, prolong the incubation period, or reduce the severity of the disease.
FRONTIERS IN IMMUNOLOGY
(2021)
